About BCL2/adenovirus E1B 19 kDa protein-interacting protein 2
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 (BNIP2) is a protein
from Homo sapiens identified by UniProt accession
Q12982, 314 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 |
| UniProt accession | Q12982 |
| Gene | BNIP2 |
| Organism | Homo sapiens |
| Length | 314 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.28
- sex hormone-binding globulin measurement · score 0.27
- mean platelet volume · score 0.24
- endometrial cancer · score 0.23
- high density lipoprotein cholesterol measurement · score 0.21
- gut microbiome measurement · score 0.18
- taxonomic microbiome measurement · score 0.18
- neutrophil percentage of leukocytes · score 0.16
- lymphocyte percentage of leukocytes · score 0.15
- macula measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q12982-F1 | alphafold | PREDICTED | 72.32 | — |
Amino-acid sequence (314 residues)
MEGVELKEEW QDEDFPIPLP EDDSIEADIL AITGPEDQPG SLEVNGNKVR KKLMAPDISL TLDPSDGSVL SDDLDESGEI DLDGLDTPSE NSNEFEWEDD LPKPKTTEVI RKGSITEYTA AEEKEDGRRW RMFRIGEQDH RVDMKAIEPY KKVISHGGYY GDGLNAIVVF AVCFMPESSQ PNYRYLMDNL FKYVIGTLEL LVAENYMIVY LNGATTRRKM PSLGWLRKCY QQIDRRLRKN LKSLIIVHPS WFIRTLLAVT RPFISSKFSQ KIRYVFNLAE LAELVPMEYV GIPECIKQVD QELNGKQDEP KNEQ
Explore BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets